Highlights from
Στιγμιότυπα για όσους δεν το παρακολουθήσατε ή για όσους προτιμήσατε τα αξιοθέατα (Museo Nacional del Prado, largest collections from artists Diego Velásquez and Francisco Goya, Reina Sofía Museum, Spain’s national museum of 20th century works, has paintings by Pablo Picasso–including Guernica–as well as Salvador Dali and οthers) and mostly Bernabeou που και προτιμήθηκε από τους περισσότερους
Υπεύθυνος προγράμματος: Tomasz Guzik, MD, PhD (University of Edinburgh,
The spotlight of this year’s meeting was “Global Health Our tagline is ‘cardiology beyond borders problems such as climate change, pandemics, lifestyle diseases, inequalities, and global conflicts that are unraveling and affecting cardiovascular disease treatment
H συμμετοχή από USA oμιλητών κάνει τη διαφορά. Μοιάζει με τις ευρωπαϊκές ομάδες basket με παίκτες από το NBA D Bhatt, Martha Gulati, GrvStone, R Lopez, Scott Solomon, Ph Genereux, M Packer, Μ Desai,S Al Khatib, J Butler, Martin Leon και ο σπουδαιότερος Ισπανός καρδιολόγος(Barcelona) V Fuster.
Χαιρετίζουμε τη παρουσία μη καρδιολόγων συμπατριωτών C. LIonis, G Stergiou, G Ntaios, Μatilda Florentin(new FESC) και των ομογενών που τιμάν τα ελληνικά χρώματα : N Dagres, Κ. Κοskinas, Papadakis, J Grapsa, Α. Βenetos E.K Oikonomou (Yale School of Medicine), Charalambos Antoniades
Aπό τους εγχώριους juniors ξεχωρίσαμε, Αγγελική Παπαγεωργίου, Ν. Μπενέτος, Αγγελική Μουράτογλου, Μαρία Δρακοπούλου, Κ Τριανταφύλλου, Sophie Mavrogen, A. karanasos, I. Leontsinis, Maria Stratinaki, Maria Marketou.(δυνατά η νέα γενιά του “ασθενούς φύλου” )
Δεν αναφέρουμε στους seniors. Πλημύρισαν τα ΜΚΔ από δικές τους αναρτήσεις. Mία της διασποράς υποψηφιότητα για Young Investigator Award preventive cardiology: Use of an AI metabolomics score to predict cardiovascular risk among patients with psoriasis in the MGB and UK
Καμια υποψηφιότητα για τα Best Clinical Cases Awards Session
ΤΙΜΗΤΙΚΑ ΒΡΑΒΕΙΑ
Οι καλύτερες εργασίες το 2024 στα European Heart Journal and Cardiovascular Research(basic discovery drive clinical delivery): για τα Desmond Julian and John Shillingford Awards αντίστοιχα
ESC Rene Laennec Lecture in Clinical Cardiology
Transcatheter treatment of structural heart disease and the emergence of interventional imagingSpeaker: Rebecca Hahn (Columbia University Medical Centre – New York, United States of America)
ESC Andreas Grüntzig Lecture in Interventional Cardiology: Intracoronary imaging: from research tool to class IA in the Guidelines Speaker: Carlo Di Mario (University of Florence – Florence, Italy)
ESC William Harvey Lecture in Basic Science: Inherited arrhythmias: novel disease mechanisms in cardiomyocytes and beyondSpeaker: Carol Ann Remme (Amsterdam University Medical Centre (AUMC) – Amsterdam
ESC Paul Hugenholtz Lecture in Innovation: Innovation in pacing therapies: where technology meets physiology. Speaker: Frits Prinzen (Cardiovascular Research Institute MaastrichtESC Geoffrey Rose Lecture in Population Sciences: Pathogenesis, diagnosis and treatment of cardiovascular disease: genetic insights Speaker: Anne Tybjaerg-Hansen (Rigshospitalet – Copenhagen University Hospital – Copenhagen, Denmark)
GUIDELINES ESC 2025 και η Ελληνική συμμετοχή. Eur Heart J in press.
Myocarditis and Pericarditis(G. Lazaros)
Valvular heart disease: The “most controversial recommendation” in the latest guideline, is likely the adjustment of the age cutoff for TAVI and SAVR to 70 from 75 years (class I, level of evidence A for TAVI and B for SAVR)
Μental health and CVD(Chr. Lionis)
CVD and pregnancy
New focused since 2019 update on the treatment of dyslipidemias: K Koskinas(chairperson), D. Righter .
Hotline Sessions 40 RCTs Σύντομη περιγραφή ΠΡΟΣΕΧΩΣ
Great Debate: για κάθε θεμα υπερ και κατά ή pro and con
Revascularisation should be performed provided there is viability
Percutaneous intervention is better than surgery in real life for most patients:
Asymptomatic aortic stenosis: does early intervention beat conservative management
Treatment of aortic stenosis and trial evidence: diminishing role for surgery in routine clinical practice?
Catheter AF ablation is more important than treating comorbidities and risk factors
Εlectrophysiology in HFrEF – the burning questions:
Atrial fibrillation ablation is the fifth pillar in the treatment of HFrEF. Discussant: Dimitrios T Farmakis (National & Kapodistrian University of Athens
Primary prevention ICD are no longer indicated in non-ischaemic HFrEF
Are really need long-term cardiac rhythm monitoring after embolic stroke of unknown source (ESUS)
Ηuman vs. machine – cardiac imaging in 2030 – who wins the heart?
The end of the imager: how AI is set to dominate
Tackling the obesity tsunami: pharmacotherapy with GLP-1 is the solution
Following an ACS, the default duration of dual antiplatelet therapy should be 12 months
To clip or not to clip? – that is the question. Mάχη γιγάντων
Percutaneous mitral valve repair should have a Class I recommendation for the management of significant secondary mitral regurgitation in heart failure: proSpeaker: Gregg Stone (Icahn School of Medicine at Mount Sinai – New York, United States of America)
Percutaneous mitral valve repair should have a Class I recommendation for the management of significant secondary mitral regurgitation in heart failure: conSpeaker: Milton Packer (Baylor University Medical Center – Dallas, United States of America)
Conduction system pacing – have we found the Holy Grail of physiological pacing? Will replace right ventricular pacing around the world:
Stroke prevention in specific clinical scenarios: Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy –
Pulsed field ablation should reduce the threshold for ablation in ΑF
Left atrial appendage closure in anticoagulant-eligible patients with atrial fibrillation: pro Apostolos Tzikas (Hippokration Thessaloniki –
TAVI should be the first procedure if a biological valve is chosen
All my patients need a coronary computed tomography:
Valvular heart disease – is the key in the myocardium or the valve?
Long-term surveillance of first-degree relatives is required in gene-elusive cardiomyopathies
Anti-inflammatory therapy should be a part of atherosclerotic cardiac disease treatment
Renal denervation is one of the pillars of management of resistant hypertension
GLP-1 receptor agonists therapy induces muscle loss in cardiometabolic disease:
Human vs. machine(AI) – cardiac imaging in 2030 – who wins the heart?
Discussant: Maria Marketou (University Hospital of Heraklion -Greece)
The rise of artificial intelligence-avatars in cardiology – will they solve disparities?
Controversies in the management of cardiogenic shock in ACSs:
All patients should be considered for mechanical circulatory support
All patients should be treated in specialist ‘shock’ centres
few snapshots from the ESC 25
Το 90% στις ΗΠΑ προτιμούν IVUS Ik-Kyung Jang (Massachusetts General Hospital – Boston,
To ESC 2026 Mόναχο Νάμαστε καλά
Γουδέβενος Γιάννης Γιάννινα
